Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
Authors
Du, Zhanwei
Pandey, Abhishek
Chinazzi, Matteo
Piontti, Ana Pastore Y
Publication Date
2022-05Journal Title
Nat Med
ISSN
1078-8956
Publisher
Springer Science and Business Media LLC
Volume
28
Issue
5
Pages
934-938
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Du, Z., Wang, L., Pandey, A., Lim, W. W., Chinazzi, M., Piontti, A. P. Y., Lau, E. H., et al. (2022). Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.. Nat Med, 28 (5), 934-938. https://doi.org/10.1038/s41591-022-01736-z
Description
Funder: AIR@InnoHK administered by Innovation and Technology Commission, Hong Kong
Funder: The Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Grant RG90413, and the International COVID-19 Data Alliance (ICODA), an initiative funded by the COVID-19 Therapeutics Accelerator and convened by Health Data Research UK.
Funder: the Collaborative Research Fund [Project No. C7123-20G] of the Research Grants Council of the Hong Kong SAR Government
Abstract
Given global Coronavirus Disease 2019 (COVID-19) vaccine shortages and inequity of vaccine distributions, fractionation of vaccine doses might be an effective strategy for reducing public health and economic burden, notwithstanding the emergence of new variants of concern. In this study, we developed a multi-scale model incorporating population-level transmission and individual-level vaccination to estimate the costs of hospitalization and vaccination and the economic benefits of reducing COVID-19 deaths due to dose-fractionation strategies in India. We used large-scale survey data of the willingness to pay together with data of vaccine and hospital admission costs to build the model. We found that fractional doses of vaccines could be an economically viable vaccination strategy compared to alternatives of either full-dose vaccination or no vaccination. Dose-sparing strategies could save a large number of lives, even with the emergence of new variants with higher transmissibility.
Keywords
COVID-19, COVID-19 Vaccines, Cost-Benefit Analysis, Humans, SARS-CoV-2, Vaccination, Vaccines
Sponsorship
European Commission Horizon 2020 (H2020) ERC (804744)
Identifiers
s41591-022-01736-z, 1736
External DOI: https://doi.org/10.1038/s41591-022-01736-z
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337307
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk